Clinical trial Recruiting at 3 sites Interventional Ages 65 to 80

Village-doctor–led telehealth care to improve outcomes for AF and HF in older adults

Official title: A Village Doctor-led Telehealth Supported Improvement of Outcomes of AF Patients With Heart Failure Due to Reduced or Preserved Ejection Fraction: The MIRACLE-AF 2 Heart Failure Management Trial (MIRACLE AF-HF)

Run by Jiangsu Taizhou People's Hospital · NCT07492524 · Data updated 2026-11-12

A village doctor–led telemedicine program will try to improve heart failure management in rural AF patients aged 65–80 compared with usual care.

More Heart Failure trials

Quick facts

Study typeInterventional
Ages65 Years to 80 Years
SexAll
Enrollment942 (estimated)
SponsorJiangsu Taizhou People's Hospital
Academic / other
Locations3 sites (Yancheng, Dongtai and 2 other locations)
StatusRecruiting
StartedJuly 26, 2026
Main results expectedDecember 30, 2032
Study endsDecember 30, 2032
Registry record updatedOctober 7, 2026
Trial IDNCT07492524 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 65–80 with atrial fibrillation and a history of heart failure living in rural Jiangsu province and managed at participating village clinics.

Probably not a fit

Patients who do not have access to reliable telemedicine, or whose HF/AF are managed well with current care, may see little to no additional benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This cluster-randomized trial tests a telemedicine-supported, village doctor–led integrated care model for adults 65–80 with atrial fibrillation and heart failure in rural China. The model emphasizes ABC pathway-based management, regular follow-up, medication review, risk monitoring, guideline-directed therapy, timely specialist input, and structured patient education. Phase 1 assesses HF risk scores at 12 months, while Phase 2 looks at a composite cardiovascular endpoint over 36 months, with an observational follow-up at year 6. The study aims to determine if decentralized, primary-care–driven care can reduce adverse cardiovascular events and improve guideline-concordant treatment in a resource-limited rural setting.

Why it matters

Potential benefit: If successful, patients could experience lower risk of heart failure–related events and improved overall heart health through accessible, doctor-led telemedicine in rural areas.

How similar studies have gone: Prior work suggests integrated, guideline-based care improves AF management, but this village-doctor–led model in rural China is a novel approach with limited prior evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The village clinics need to be willing and able to provide integrated care to their patients with atrial fibrillation; 2. The village doctors from one village clinic serves all AF patients from 3-5 nearby villages; 3. The village doctors are trained to have a fundamental understanding of telemedicine; 4. Patients are eligible for participation if 1)they aged 65-80 years. 2) Electrocardiogram (ECG) confirmation of AF or possession of a diagnostic certificate for AF issued by a specialist. 3) A documented history of HF, or newly diagnosed HF according to the 2026 ESC Guidelines for the management of heart failure. HF will require current or prior typical symptoms and/or signs attributable to a structural and/or functional cardiac abnormality. Participants with LVEF \<50% will be classified as having heart failure with reduced ejection fraction (HFrEF). In participants with LVEF ≥50%, heart failure with preserved ejection fraction (HFpEF) will require objective evidence of cardiac structural and/or functional abnormalities consistent with left ventricular diastolic dysfunction or elevated filling pressures, supported by elevated natriuretic peptide levels. In participants with AF, supportive echocardiographic abnormalities will include left atrial volume index (LAVI) \>40 mL/m², E/e' \>15, pulmonary artery systolic pressure \>35 mmHg, or tricuspid regurgitation velocity \>2.8 m/s. 4) Management by a village clinic near the participant's place of residence. 5) Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria:

1. Expected life expectancy of less than 12 months.
2. Severe renal insufficiency (Ccr \< 30ml/min) or ongoing dialysis treatment.
3. Cardiac insufficiency secondary to correctable causes, including hyperthyroid heart disease, anemic heart disease, or uncorrected congenital heart disease.
4. Indications for pacemaker implantation without having undergone implantation.
5. Chronic obstructive pulmonary disease (COPD) complicated by type II respiratory failure.
6. Special populations, including patients with mental illnesses.

Where it's running

  • Village Clinics in Dongtai City, Jiangsu Province
    Yancheng, Dongtai, China
    Recruiting
  • Village Clinics in Jiangdu District, Jiangsu Province
    Yangzhou, Jiangdu, China
    Recruiting
  • Village Clinics in Suining County, Jiangsu Province
    Xuzhou, Suining, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.